Multihance

Active Ingredient:: Gadobenate Dimeglumine
Origin:: EU

Multihance (Gadobenate Dimeglumine)

Q: What is Multihance used for?

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve the visibility of structures in the brain, spinal cord, liver, cardiovascular system, and the abdomen and pelvis. By enhancing T1‑weighted images, it helps radiologists detect lesions, vascular abnormalities, and other pathologies with greater clarity.

Q: How does Gadobenate dimeglumine work?

Gadobenate dimeglumine shortens the T1 relaxation time of nearby water protons after intravenous injection. Its weak binding to serum albumin raises its relaxivity, producing a stronger signal on T1‑weighted MRI sequences. This increased signal intensity makes tissues and blood vessels appear brighter, aiding diagnostic interpretation.

Q: What is the usual dose of Multihance?

The dose of Multihance is determined by the prescribing physician based on the patient’s weight, renal function, and the specific imaging protocol. Typical dosing follows the manufacturer’s guidelines for the intended MRI study, but exact amounts are individualized and should not be altered without medical direction.

Q: Is Multihance safe in pregnancy or breastfeeding?

The safety of Gadobenate dimeglumine during pregnancy and lactation has not been established, and it is classified as a category unknown agent. Use is only considered when the diagnostic benefit outweighs potential risks to the fetus or infant, and it should be administered under close medical supervision.

Q: How do I order Multihance from GNH India?

To order Multihance, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Q: How does Multihance compare with the main alternative contrast agents?

Multihance (gadobenate dimeglumine) offers higher relaxivity than many conventional gadolinium agents, providing stronger T1 enhancement, especially in vascular imaging. Compared with agents such as gadobutrol (Gadovist), Multihance may achieve comparable image quality at lower doses but shares similar safety considerations, including the risk of NSF in patients with severe renal impairment.

Q: What are the storage and handling requirements for Multihance?

Multihance should be stored at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles. Follow standard aseptic techniques when preparing for intravenous administration.

Q: How is Multihance administered?

Multihance is administered as an intravenous injection, usually as a rapid bolus followed by a saline flush. The injection is performed by a qualified healthcare professional using aseptic technique, and patients are monitored during and after the injection for any immediate adverse reactions.

Q: What are the most serious risks associated with Multihance?

The most serious risks include severe allergic reactions such as anaphylaxis, nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, and profound hypotension that can lead to syncope or cardiac arrest. Immediate medical attention is required if any of these events occur.

Q: Who should not use Multihance?

Multihance should be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), a known hypersensitivity to gadolinium‑based agents, or a history of NSF. Caution is also advised for patients with uncontrolled asthma, severe cardiac disease, or those who are pregnant or breastfeeding unless the diagnostic benefit justifies the risk.

Gadobenate dimeglumine, the active ingredient in Multihance, is a paramagnetic MRI contrast agent presented as a 0.5 mmol/mL solution for injection for intravenous use. It enhances T1‑weighted magnetic resonance imaging of the brain, spinal cord, liver, cardiovascular system and other abdominal and pelvic structures, providing clearer diagnostic images.

GNH India supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. All shipments meet EU regulatory standards and are handled under strict quality‑assurance protocols. The product is manufactured under GMP conditions to ensure consistent safety and efficacy.

Manufacturer / TM Owner

Bracco Imaging S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Multihance is a paramagnetic contrast agent used to improve magnetic resonance imaging across several organ systems.

Brain and spinal cord MRI: provides enhanced visualization of lesions, tumors and vascular structures.
Liver MRI: improves detection and characterization of focal hepatic lesions.
Cardiovascular MRI: enhances delineation of cardiac chambers, myocardium and vascular anatomy.
Magnetic resonance angiography (MRA): increases signal intensity for clearer arterial and venous mapping.
Abdomen and pelvis MRI: offers better contrast for organs and soft‑tissue assessment.

How It Works

Gadobenate dimeglumine is a gadolinium‑based contrast agent that shortens the T1 relaxation time of nearby water protons. After intravenous administration, the agent distributes into the extracellular fluid and binds weakly to serum albumin, which raises its relaxivity. The resulting increase in signal intensity on T1‑weighted MRI sequences allows radiologists to obtain high‑resolution images of vascular and tissue structures. This effect is particularly useful for differentiating pathological from normal tissue.

Side Effects

Gadobenate dimeglumine may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects

Nausea: mild to moderate feeling of queasiness.
Headache: transient pain in the head region.
Warmth sensation: brief feeling of heat at the injection site.
Injection site pain: mild discomfort where the drug is administered.

Serious or Rare Side Effects

Anaphylactic reaction: severe allergic response requiring immediate medical attention.
Nephrogenic systemic fibrosis: rare fibrotic disorder in patients with severe renal impairment.
Severe hypotension: marked drop in blood pressure that may cause dizziness or fainting.
Cardiac arrest: rare but life‑threatening cessation of heart activity.

Precautions & Warnings

Prior to using Multihance, several safety considerations should be evaluated to minimize risk.

Renal function assessment: evaluate glomerular filtration rate, especially in patients with known kidney disease.
Avoid in severe renal impairment: contraindicated in patients with GFR <30 mL/min/1.73 m² due to NSF risk.
Monitor for allergic reactions: observe patients during and after injection for signs of hypersensitivity.
Use with caution in pregnancy: safety not established; weigh diagnostic benefit against potential fetal exposure.
Discontinue if prior gadolinium reaction: avoid re‑exposure in individuals with documented hypersensitivity.
Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Gadobenate dimeglumine can interact with certain drugs or conditions, influencing safety or efficacy.

Major Interactions (Avoid)

Concurrent use of other gadolinium agents: may increase cumulative gadolinium exposure.
Renally toxic medications (e.g., aminoglycosides, NSAIDs): can exacerbate renal impairment and raise NSF risk.

Moderate Interactions (Monitor Closely)

Iron chelators (e.g., deferoxamine): may alter gadolinium distribution.
Beta‑blockers: may mask hypotensive responses during injection.
Diuretics: can affect renal clearance of the contrast agent.

Frequently Asked Questions

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve the visibility of structures in the brain, spinal cord, liver, cardiovascular system, and the abdomen and pelvis. By enhancing T1‑weighted images, it helps radiologists detect lesions, vascular abnormalities, and other pathologies with greater clarity.

Gadobenate dimeglumine shortens the T1 relaxation time of nearby water protons after intravenous injection. Its weak binding to serum albumin raises its relaxivity, producing a stronger signal on T1‑weighted MRI sequences. This increased signal intensity makes tissues and blood vessels appear brighter, aiding diagnostic interpretation.

The dose of Multihance is determined by the prescribing physician based on the patient’s weight, renal function, and the specific imaging protocol. Typical dosing follows the manufacturer’s guidelines for the intended MRI study, but exact amounts are individualized and should not be altered without medical direction.

The safety of Gadobenate dimeglumine during pregnancy and lactation has not been established, and it is classified as a category unknown agent. Use is only considered when the diagnostic benefit outweighs potential risks to the fetus or infant, and it should be administered under close medical supervision.

To order Multihance, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Multihance (gadobenate dimeglumine) offers higher relaxivity than many conventional gadolinium agents, providing stronger T1 enhancement, especially in vascular imaging. Compared with agents such as gadobutrol (Gadovist), Multihance may achieve comparable image quality at lower doses but shares similar safety considerations, including the risk of NSF in patients with severe renal impairment.

Multihance should be stored at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles. Follow standard aseptic techniques when preparing for intravenous administration.

Multihance is administered as an intravenous injection, usually as a rapid bolus followed by a saline flush. The injection is performed by a qualified healthcare professional using aseptic technique, and patients are monitored during and after the injection for any immediate adverse reactions.

The most serious risks include severe allergic reactions such as anaphylaxis, nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, and profound hypotension that can lead to syncope or cardiac arrest. Immediate medical attention is required if any of these events occur.

Multihance should be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), a known hypersensitivity to gadolinium‑based agents, or a history of NSF. Caution is also advised for patients with uncontrolled asthma, severe cardiac disease, or those who are pregnant or breastfeeding unless the diagnostic benefit justifies the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.